Belite Bio (BLTE) Competitors

Belite Bio (NASDAQ:BLTE) and Blueprint Medicines (NASDAQ:BPMC) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, community ranking, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Is BLTE or BPMC more profitable?

Belite Bio has a net margin of 0.00% compared to Blueprint Medicines' net margin of -13.19%. Belite Bio's return on equity of -31.94% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-31.94%	-30.73%
Blueprint Medicines	-13.19%	-77.49%	-20.84%

Do analysts recommend BLTE or BPMC?

Belite Bio currently has a consensus target price of $96.33, suggesting a potential upside of 69.01%. Blueprint Medicines has a consensus target price of $123.83, suggesting a potential upside of 34.24%. Given Belite Bio's stronger consensus rating and higher probable upside, equities analysts clearly believe Belite Bio is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	0 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	3.00
Blueprint Medicines	1 Sell rating(s)	6 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.65

Do institutionals and insiders believe in BLTE or BPMC?

0.5% of Belite Bio shares are held by institutional investors. 13.3% of Belite Bio shares are held by company insiders. Comparatively, 4.2% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Does the media prefer BLTE or BPMC?

In the previous week, Blueprint Medicines had 19 more articles in the media than Belite Bio. MarketBeat recorded 20 mentions for Blueprint Medicines and 1 mentions for Belite Bio. Belite Bio's average media sentiment score of 1.50 beat Blueprint Medicines' score of 0.26 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Blueprint Medicines	5 Very Positive mention(s)	0 Positive mention(s)	8 Neutral mention(s)	2 Negative mention(s)	1 Very Negative mention(s)	Neutral

Which has higher valuation & earnings, BLTE or BPMC?

Belite Bio has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$31.63M	-$1.11	-51.35
Blueprint Medicines	$508.82M	11.59	-$67.09M	-$1.08	-85.42

Which has more risk & volatility, BLTE or BPMC?

Belite Bio has a beta of -1.59, suggesting that its share price is 259% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500.

Does the MarketBeat Community believe in BLTE or BPMC?

Blueprint Medicines received 514 more outperform votes than Belite Bio when rated by MarketBeat users. However, 96.88% of users gave Belite Bio an outperform vote while only 68.13% of users gave Blueprint Medicines an outperform vote.

Company	Underperform	Outperform
Belite Bio	Outperform Votes 31 96.88%	Underperform Votes 1 3.13%
Blueprint Medicines	Outperform Votes 545 68.13%	Underperform Votes 255 31.88%

Summary

Belite Bio beats Blueprint Medicines on 10 of the 18 factors compared between the two stocks.